PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24259417-7 2014 Additionally, we determined the role of the aspirin-triggered 17R analog (AT-RvD1, a more chemically stable RvD1 epimeric form) in prevention of TNF-alpha-mediated salivary inflammation in mouse submandibular glands (mSMG). Aspirin 44-51 tumor necrosis factor Mus musculus 145-154 25824964-7 2015 Aspirin counteracted TNF-alpha-mediated effects on netrin-1 synthesis by endothelial cells through COX-dependent inhibition of NF-kappaB and concomitant histone hyperacetylation. Aspirin 0-7 tumor necrosis factor Mus musculus 21-30 20169081-5 2010 Supporting a role for PGE(2) we observed that acetylsalicylic acid impaired the ability of MSC to inhibit the production of inflammatory cytokines and to stimulate the production of IL-10 by LPS-stimulated M. Moreover, we found that MSC constitutively produce PGE2 at levels able to inhibit the production of TNF-alpha and IL-6 by activated M. MSC also inhibited the up-regulation of CD86 and MHC class II in LPS-stimulated M impairing their ability to activate antigen-specific T CD4+ cells. Aspirin 46-66 tumor necrosis factor Mus musculus 309-318 23553791-6 2013 Systemic administration of aspirin, which significantly reduces the levels of IFN-gamma and TNF-alpha, results in blockage of MSC deficiency and tumorigenesis by inhibition of NFkappaB/SMAD7 and NFkappaB/c-FOS and c-MYC pathways in OVX mice. Aspirin 27-34 tumor necrosis factor Mus musculus 92-101 23653362-7 2013 Furthermore, we demonstrate that aspirin-induced astroglial CNTF was also functionally active and that supernatants of aspirin-treated astrocytes of wild type, but not Cntf null, mice increased myelin-associated proteins in oligodendrocytes and protected oligodendrocytes from TNF-alpha insult. Aspirin 33-40 tumor necrosis factor Mus musculus 277-286 23653362-7 2013 Furthermore, we demonstrate that aspirin-induced astroglial CNTF was also functionally active and that supernatants of aspirin-treated astrocytes of wild type, but not Cntf null, mice increased myelin-associated proteins in oligodendrocytes and protected oligodendrocytes from TNF-alpha insult. Aspirin 119-126 tumor necrosis factor Mus musculus 277-286 21347238-10 2011 Expression of SOCS-2 was enhanced, and TRAF6 and TNFalpha reduced, in the spleens of infected ASA-treated mice. Aspirin 94-97 tumor necrosis factor Mus musculus 49-57 20690072-7 2011 The results showed that administration with aspirin for 4 weeks or 8 weeks significantly reduced the mean escape latency, the acetylcholinesterase activity, the TNF-alpha, IL-1beta levels and increased the percentage of time spent in target quadrant. Aspirin 44-51 tumor necrosis factor Mus musculus 161-170 18308578-9 2008 Both aspirin and enoxaparin normalized brain concentrations of PGE and TNF-alpha and elevated thrombin inhibitors, the latter effect being more pronounced for enoxaparin. Aspirin 5-12 tumor necrosis factor Mus musculus 71-80 18625344-7 2008 In addition, the aspirin nano-emulsion further reduced the auricular levels of IL-1alpha (-37%) and TNFalpha (-69%) compared to the aspirin suspension preparation (p<0.05). Aspirin 17-24 tumor necrosis factor Mus musculus 100-108 9383683-7 1997 The increase in NO production in response to IL-1 alpha and TNF-alpha was further stimulated by aspirin and inhibited by exogenous addition of PGE2, suggesting that PGE2 produced by the cytokines, in turn, negatively modulates NO production. Aspirin 96-103 tumor necrosis factor Mus musculus 60-69 17390393-9 2007 Treatment with the PGE(2) synthesis inhibitor acetylsalicylic acid (AAS) in vivo reduced parasitemia and enhanced LPS-stimulated production of TNF by macrophages, but the effect was less in infected mice than in normal mice. Aspirin 46-66 tumor necrosis factor Mus musculus 143-146 12879250-11 2003 The inhibition of PNF by AsA was associated with decreased intra-islet levels of inflammation-related molecules (IL-1, TNF-alpha, iNOS, COX-2) and chemokines (MCP-1 and MIP-3alpha). Aspirin 25-28 tumor necrosis factor Mus musculus 119-128 15775706-6 2005 However, at doses of 200 and 300 mg/kg, ASA or ACET significantly and dose-dependently attenuated pain behavior induced by TNF-alpha, IL-1beta or IFN-gamma administered intrathecally. Aspirin 40-43 tumor necrosis factor Mus musculus 123-132 15775706-7 2005 Our results suggest that orally administered ASA and ACET produce antinociception by inhibiting the nociceptive action of TNF-alpha, IL-1beta or IFN-gamma administered intrathecally. Aspirin 45-48 tumor necrosis factor Mus musculus 122-131 12451498-7 2002 The fact that aspirin but not H7 blocks the enhancing effect suggests that NF-kappaB might be involved in wogonin-enhanced TNF-alpha gene expression. Aspirin 14-21 tumor necrosis factor Mus musculus 123-132 10648469-7 2000 At a dose of 100 mg/kg, NO-aspirin caused a 40%-80% reduction of interleukin (IL)-1beta, IL-12, IL-18, interferon (IFN)-gamma, and tumor necrosis factor alpha production without affecting cytokine messenger RNA expression. Aspirin 27-34 tumor necrosis factor Mus musculus 131-158 9471925-25 1997 The acetylsalicylic acid had an inhibitory effect on the release of nitrites, PGF2 alpha and TNF alpha (Tab. Aspirin 4-24 tumor necrosis factor Mus musculus 93-102 9281604-2 1997 This observation led us to investigate the role of aspirin in suppressing the activation of the NF-kappaB-regulated tumor necrosis factor-alpha (TNF-alpha) gene expression in primary macrophages. Aspirin 51-58 tumor necrosis factor Mus musculus 116-143 9281604-2 1997 This observation led us to investigate the role of aspirin in suppressing the activation of the NF-kappaB-regulated tumor necrosis factor-alpha (TNF-alpha) gene expression in primary macrophages. Aspirin 51-58 tumor necrosis factor Mus musculus 145-154 9281604-3 1997 We now report that therapeutic doses of aspirin suppress lipopolysaccharide-inducible NF-kappaB binding to an NF-kappaB binding site in the TNF-alpha promoter, lipopolysaccharide-induced TNF-alpha mRNA accumulation, and protein secretion. Aspirin 40-47 tumor necrosis factor Mus musculus 140-149 9281604-3 1997 We now report that therapeutic doses of aspirin suppress lipopolysaccharide-inducible NF-kappaB binding to an NF-kappaB binding site in the TNF-alpha promoter, lipopolysaccharide-induced TNF-alpha mRNA accumulation, and protein secretion. Aspirin 40-47 tumor necrosis factor Mus musculus 187-196 9281604-5 1997 The aspirin-initiated stabilization of IkappaB, suppression of induced TNF-alpha mRNA, and NF-kappaB binding to the TNF-alpha promoter are blocked by pretreatment with pertussis toxin. Aspirin 4-11 tumor necrosis factor Mus musculus 71-80 9281604-5 1997 The aspirin-initiated stabilization of IkappaB, suppression of induced TNF-alpha mRNA, and NF-kappaB binding to the TNF-alpha promoter are blocked by pretreatment with pertussis toxin. Aspirin 4-11 tumor necrosis factor Mus musculus 116-125 32933639-11 2020 Compared with the low-dose ginsenoside Rb1 group, the aspirin group and the high-dose ginsenoside Rb1 group had significant reductions in the levels of TNF-alpha, IL-6, and IL-1beta (P<0.05); the high-dose ginsenoside Rb1 group had significant increases in the expression levels of P-PI3K/PI3K and P-AKT/AKT (P<0.05). Aspirin 54-61 tumor necrosis factor Mus musculus 152-161 34857988-8 2021 Aspirin also significantly decreased tumor necrosis factor alpha and reactive oxygen species (ROS) levels in the plasma. Aspirin 0-7 tumor necrosis factor Mus musculus 37-64 34208905-6 2021 Compared to the non-pretreated group, the pretreatment group with simultaneous enteral aspirin and omega-3 fatty acid showed reduced expression of the pro-inflammatory cytokine, tumor necrosis factor-alpha, in bronchoalveolar lavage fluid (p = 0.038). Aspirin 87-94 tumor necrosis factor Mus musculus 178-205 35111059-12 2021 Posttreatment with aspirin also reduced hyperoxia-induced increases in the numbers of lung macrophages, intracellular ROS levels, and the expression of TNF-alpha, IL-1beta, and IL-4; it also increased CC10, SPC and Nrp-1 levels compared with hyperoxia exposure alone. Aspirin 19-26 tumor necrosis factor Mus musculus 152-161 33313269-14 2020 Moreover, aspirin reduced the levels of inflammatory factors interleukin-6, interleukin-1beta and tumor necrosis factor-alpha and decreased the activation of STAT3 signaling pathway. Aspirin 10-17 tumor necrosis factor Mus musculus 98-125 32429142-11 2020 In addition, we demonstrated that pretreatment with aspirin significantly reduced the protein levels of phosphorylated protein kinase B, NF-kappaB and tumor necrosis factor alpha in NF-kappaB-luciferase+/+ transgenic mice. Aspirin 52-59 tumor necrosis factor Mus musculus 151-178 32629916-6 2020 The results revealed that aspirin inhibited macrophage chemoattractant protein (MCP-1), interleukin (IL-6), IL-1beta, and plasminogen activator inhibitor (PAI-1) production in 3T3-L1 adipocytes stimulated by tumor necrosis factor-alpha (TNF-alpha) and lipopolysaccharide (LPS). Aspirin 26-33 tumor necrosis factor Mus musculus 208-235 32629916-6 2020 The results revealed that aspirin inhibited macrophage chemoattractant protein (MCP-1), interleukin (IL-6), IL-1beta, and plasminogen activator inhibitor (PAI-1) production in 3T3-L1 adipocytes stimulated by tumor necrosis factor-alpha (TNF-alpha) and lipopolysaccharide (LPS). Aspirin 26-33 tumor necrosis factor Mus musculus 237-246 29185103-14 2017 Aspirin, ticagrelor, and rosuvastatin all decreased TNF-alpha levels. Aspirin 0-7 tumor necrosis factor Mus musculus 52-61 27207670-9 2016 Furthermore, AOM/DSS + ASA inhibited AOM/DSS-induced enrichment of H3K27ac in the promoters of inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) that corresponded to the dramatic suppression of the messenger RNA (mRNA) and protein levels. Aspirin 23-26 tumor necrosis factor Mus musculus 135-162 29285098-7 2017 Furthermore, subsequent to inhibition of the MAPK pathway by specific inhibitors (PD98059, SB203580 and SP600125), the expression of MMP-9 was reduced, indicating that the inhibitory effect of aspirin on MMP-9 in TNF-alpha-treated RAW264.7 cells may be, at least in part, through suppression of NF-kappaB activation and the MAPK pathway. Aspirin 193-200 tumor necrosis factor Mus musculus 213-222 29285098-0 2017 Aspirin suppresses TNF-alpha-induced MMP-9 expression via NF-kappaB and MAPK signaling pathways in RAW264.7 cells. Aspirin 0-7 tumor necrosis factor Mus musculus 19-28 29285098-3 2017 The present study aimed to investigate the pharmacological effects of aspirin on tumor necrosis factor-alpha (TNF-alpha)-induced MMP-9 expression and the underlying molecular mechanisms in murine macrophage RAW264.7 cells. Aspirin 70-77 tumor necrosis factor Mus musculus 81-108 29285098-3 2017 The present study aimed to investigate the pharmacological effects of aspirin on tumor necrosis factor-alpha (TNF-alpha)-induced MMP-9 expression and the underlying molecular mechanisms in murine macrophage RAW264.7 cells. Aspirin 70-77 tumor necrosis factor Mus musculus 110-119 28912509-4 2017 We found that ASA could downregulate the expressions of iNOS and TNF-alpha both in mouse peritoneum macrophages and RAW264.7 cells induced by LPS via the IkappaK/IkappaB/NF-kappaB pathway and a COX2/PGE2/EP2/NF-kappaB feedback loop, without affecting the expressions of FIZZ/YM-1/ARG1 induced by IL-4. Aspirin 14-17 tumor necrosis factor Mus musculus 65-74 27207670-9 2016 Furthermore, AOM/DSS + ASA inhibited AOM/DSS-induced enrichment of H3K27ac in the promoters of inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha (TNF-alpha) and interleukin 6 (IL-6) that corresponded to the dramatic suppression of the messenger RNA (mRNA) and protein levels. Aspirin 23-26 tumor necrosis factor Mus musculus 164-173 27207670-11 2016 Collectively, our results suggest that a potential novel epigenetic mechanism underlies the chemopreventive effects of ASA, and this mechanism attenuates CAC in AOM/DSS-induced CF-1 mice via the inhibition of HDACs and the modification of H3K27ac marks that suppress iNOS, TNF-alpha and IL-6. Aspirin 119-122 tumor necrosis factor Mus musculus 273-282 26794215-6 2016 The results showed that aspirin treatment inhibited differentiation and lipid accumulation by 3T3-L1 preadipocytes, and decreased the secretion of the inflammatory adipokine MCP-1 after stimulation with tumor necrosis factor (TNF)-alpha or conditioned medium from RAW264.7 cells. Aspirin 24-31 tumor necrosis factor Mus musculus 203-236 26522688-4 2015 We also showed that TfR1 and Fpn1 expressions were significantly higher, while ferritin contents, IL-6, TNF-alpha and hepcidin mRNA levels were lower in cells treated with aspirin plus LPS than those in cells treated with LPS only. Aspirin 172-179 tumor necrosis factor Mus musculus 104-113